慢性阻塞性肺病和氣喘治療設備市場規模、佔有率和成長分析（按產品、適應症、通路和地區分類）—產業預測（2026-2033 年）

全球 COPD 和氣喘治療設備市場規模預計在 2024 年達到 511.7 億美元，從 2025 年的 536.8 億美元成長到 2033 年的 787 億美元，在預測期（2026-2033 年）內複合年成長率為 4.9%。

由於慢性阻塞性肺病（COPD）和氣喘的盛行率不斷上升以及技術的進步，COPD和氣喘治療設備市場正經歷顯著成長。 COPD的特徵是氣流阻塞、呼吸困難和持續咳嗽等症狀，而氣喘則會損害氣道，導致喘息和胸悶，這兩種疾病都需要有效的治療方案。用於霧化吸入藥物的肺部給藥裝置在控制這些疾病中發揮關鍵作用。隨著人口老化和氣喘病例的顯著增加，對這些裝置的需求持續成長。這一趨勢顯示全球對有效呼吸護理解決方案的迫切需求，從而推動了該行業的創新和市場擴張。

推動全球慢性阻塞性肺病和氣喘治療設備市場發展的因素

慢性阻塞性肺病（COPD）、氣喘和肺氣腫等呼吸系統疾病的日益流行是全球COPD和氣喘治療設備市場的主要驅動力。這種日益成長的盛行率推動了人們對即時有效治療方法（包括急救藥物）的需求，尤其是在氣喘發作期間。此外，政府為提高公眾對COPD和氣喘症狀的認知而採取的措施也促進了市場成長。同時，製造商正日益專注於創新和開發攜帶式吸入器，隨著患者尋求更便利且高效的呼吸管理方案，這進一步推動了該市場的擴張。

限制全球慢性阻塞性肺病和氣喘治療設備市場的因素

全球慢性阻塞性肺病（COPD）和氣喘治療設備市場的成長可能受到多種因素的阻礙。與定量噴霧吸入器（MDI）相關的環境問題以及各種吸入設備和治療方法的高成本都加劇了市場挑戰。激烈的價格競爭也可能進一步影響盈利。此外，報銷支持不足和關鍵藥物專利到期等問題也可能限制該領域的擴張機會。另外，用於製造這些設備的材料品質下降也對市場發展構成了額外的障礙。

全球慢性阻塞性肺病和氣喘治療設備市場趨勢

受數位吸入器技術進步的推動，全球慢性阻塞性肺病（COPD）和氣喘治療設備市場正經歷顯著成長。這些創新設備不僅能將藥物直接輸送到肺部，最大限度地減少全身副作用，還提供先進的監測和依從性支持功能，從而改善患者的治療效果。隨著醫療保健領域越來越重視個人化和預防性治療方法，對客製化呼吸系統解決方案的需求也日益成長。吸入器使用不當和依從性低等挑戰，促使人們開發出易於使用的設備，這些設備整合了病患教育工具和即時回饋功能，最終目標是減少病情加重，並改善慢性呼吸系統疾病的管理。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二手資料和一手資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2025）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析

全球慢性阻塞性肺病和氣喘治療設備市場規模（按產品和複合年成長率分類）（2026-2033 年）

• 吸入器
  • 藥物粉末吸入器（DPI）
  • 定量噴霧吸入器（MDI）
  • 緩霧吸入器
• 噴霧器
  • 壓縮式霧化器
  • 超音波霧化器
  • 網狀霧化器

全球慢性阻塞性肺病和氣喘治療設備市場規模（按適應症和複合年成長率分類）（2026-2033 年）

• 氣喘
• COPD

全球慢性阻塞性肺病和氣喘治療設備市場規模（按分銷管道和複合年成長率分類）（2026-2033 年）

• 零售藥房
• 醫院
• 網路藥房

全球慢性阻塞性肺病及氣喘治療設備市場規模及複合年成長率（2026-2033）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 依業務板塊進行公司股票分析
  • 2023-2025年營收年比比較

主要企業簡介

• AstraZeneca Plc.（United Kingdom）
• GlaxoSmithKline Plc.（United Kingdom）
• Merck & Co., Inc.（United States）
• Novartis AG（Switzerland）
• 3M Company（United States）
• Baxter International Inc.（United States）
• ResMed Inc.（United States）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Cipla Ltd.（India）
• Omron Healthcare, Inc.（Japan）
• Invacare Corporation（United States）
• Masimo Corporation（United States）
• Nihon Kohden Corporation（Japan）
• Getinge AB（Sweden）
• Smiths Medical（United Kingdom）
• Allied Healthcare Products, Inc.（United States）
• Aerogen Ltd.（Ireland）
• PARI Medical Holding GmbH（Germany）

結論與建議

Global COPD and Asthma Devices Market size was valued at USD 51.17 Billion in 2024 and is poised to grow from USD 53.68 Billion in 2025 to USD 78.7 Billion by 2033, growing at a CAGR of 4.9% during the forecast period (2026-2033).

The market for chronic obstructive pulmonary disease (COPD) and asthma devices is witnessing substantial growth due to the rising prevalence of these respiratory conditions and advancements in technology. COPD, characterized by airflow obstruction and symptoms such as shortness of breath and persistent cough, alongside asthma, which damages airways and can cause wheezing and chest tightness, necessitates effective treatment solutions. Pulmonary medication delivery devices, designed to aerosolize medications for inhalation, play a crucial role in managing these illnesses. With an increasing elderly population and a significant rise in asthma cases, the demand for these devices continues to soar. This trend underscores the urgent need for effective respiratory care solutions worldwide, driving innovation and market expansion in the industry.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global COPD and Asthma Devices market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global COPD and Asthma Devices Market Segments Analysis

Global COPD and Asthma Devices Market is segmented by Product, Indication, Distribution Channel and region. Based on Product, the market is segmented into Inhalers and Nebulizers. Based on Indication, the market is segmented into Asthma and COPD. Based on Distribution Channel, the market is segmented into Retail Pharmacies, Hospitals and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global COPD and Asthma Devices Market

The global market for COPD and asthma devices is being significantly propelled by the increasing incidence of respiratory conditions such as COPD, asthma, and emphysema. This rise in prevalence has led to an amplified demand for immediate and effective treatments, particularly rescue medications during sudden asthma attacks. Moreover, government initiatives aimed at improving awareness of COPD and asthma symptoms are contributing to market growth. Simultaneously, manufacturers are intensifying their efforts to innovate and develop portable inhalation devices, further driving the expansion of this market as patients seek more convenient and efficient solutions for managing their respiratory difficulties.

Restraints in the Global COPD and Asthma Devices Market

The growth of the global COPD and asthma devices market is likely to be hindered by several factors. Environmental concerns associated with metered dose inhalers (MDIs) contribute to market challenges, alongside the high costs associated with a variety of inhalation devices and treatments. The presence of intense price competition can further impact profitability. Additionally, issues such as inadequate reimbursement support and the expiration of patents for significant medications may limit expansion opportunities in this sector. Furthermore, the decline in quality of materials used in the production of these devices presents additional obstacles that could impede market progress.

Market Trends of the Global COPD and Asthma Devices Market

The Global COPD and Asthma Devices market is experiencing significant growth driven by advancements in digital inhaler technology. These innovative devices not only enhance medication delivery directly to the lungs, minimizing systemic side effects but also offer sophisticated monitoring and adherence features that improve patient outcomes. As the healthcare sector increasingly prioritizes personalized and proactive treatment approaches, the demand for tailored respiratory solutions is surging. Challenges such as incorrect inhaler technique and low adherence rates are prompting the development of user-friendly devices that integrate educational tools and real-time feedback for patients, ultimately aiming to reduce exacerbations and enhance the management of chronic respiratory diseases.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global COPD and Asthma Devices Market Size by Product & CAGR (2026-2033)

• Market Overview
• Inhalers
  • Drug Powdered Inhalers (DPIs)
  • Metered Dose Inhalers (MDIs)
  • Soft Mist Inhalers
• Nebulizers
  • Compressor Nebulizers
  • Ultrasonic Nebulizers
  • Mesh Nebulizers

Global COPD and Asthma Devices Market Size by Indication & CAGR (2026-2033)

• Market Overview
• Asthma
• COPD

Global COPD and Asthma Devices Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Retail Pharmacies
• Hospitals
• Online Pharmacies

Global COPD and Asthma Devices Market Size & CAGR (2026-2033)

• North America (Product, Indication, Distribution Channel)
  • US
  • Canada
• Europe (Product, Indication, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Indication, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Indication, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Indication, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• AstraZeneca Plc. (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline Plc. (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• 3M Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Baxter International Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ResMed Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Omron Healthcare, Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Invacare Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Masimo Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nihon Kohden Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Getinge AB (Sweden)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Smiths Medical (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Allied Healthcare Products, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aerogen Ltd. (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PARI Medical Holding GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations